Last updated: October 27, 2026
Mucinex D is a U.S. over-the-counter combination of extended-release guaifenesin and pseudoephedrine. Reckitt owns and markets the Mucinex brand. The product has no conventional prescription-drug exclusivity period and does not rely on a single blocking patent. Its commercial position depends on brand recognition, pharmacist-controlled pseudoephedrine access, retail distribution, formulation execution, and competition from store brands and other decongestants.
Reckitt does not publicly disclose Mucinex D revenue as a separate line item. Product-level revenue, gross margin, and market share therefore cannot be calculated from public company filings. The available evidence supports a mature, cash-generative OTC brand with modest volume growth potential and continuing pricing and mix support.
What is Mucinex D and how does the product work?
Mucinex D combines two active ingredients:
| Active ingredient |
Function |
Typical extended-release role |
| Guaifenesin |
Expectorant |
Loosens and thins bronchial mucus |
| Pseudoephedrine hydrochloride |
Nasal decongestant |
Reduces nasal congestion through vasoconstriction |
Mucinex D is sold in extended-release tablet presentations, including regular-strength and maximum-strength versions. Product labeling directs consumers to swallow tablets whole and limits dosing by age and formulation. The product is marketed for congestion associated with colds, allergies, and related upper-respiratory conditions. FDA labeling states that Mucinex D is intended for temporary relief and does not treat the underlying cause of infection.[1]
Pseudoephedrine is the commercially important component. It differentiates Mucinex D from Mucinex products containing guaifenesin alone, but it also creates regulatory and channel constraints.
How large is the Mucinex D market?
The relevant market is the U.S. cough, cold, allergy, and oral decongestant category. Mucinex D competes across several overlapping segments:
- Branded expectorants such as Mucinex and Mucinex DM.
- Branded oral decongestants such as Sudafed.
- Combination cold products such as Advil Cold & Sinus, Aleve-D, and store-brand equivalents.
- Private-label guaifenesin and pseudoephedrine products.
- Phenylephrine-based products sold on open retail shelves.
- Nonoral treatments, including nasal sprays, antihistamines, and saline products.
The addressable market is seasonal. Demand typically increases during fall and winter respiratory illness periods, with weather, influenza prevalence, allergy seasons, and consumer health concerns affecting volume. Mucinex D also benefits from consumers seeking an expectorant and a stronger oral decongestant in one product.
Retail sales are constrained by pseudoephedrine purchasing rules. Federal law limits retail pseudoephedrine sales to 3.6 grams per day and 9 grams per 30-day period, with lower limits for mail-order transactions. Retailers must maintain transaction records and verify purchaser identity.[2] These requirements create friction for consumers and increase compliance costs for retailers.
What is the financial trajectory for Mucinex D?
Reckitt reports Mucinex within its broader consumer-health and over-the-counter portfolio rather than as a separate public reporting unit. The company’s financial statements do not provide:
- Mucinex D net revenue.
- Mucinex D unit volume.
- Mucinex D operating margin.
- U.S. versus international Mucinex D sales.
- Mucinex D advertising expenditure.
- Product-level royalty or licensing income.
The financial trajectory is therefore best assessed through category economics and Reckitt’s portfolio strategy.
| Financial driver |
Direction for Mucinex D |
Business effect |
| Brand pricing |
Positive |
Supports revenue when unit volume is flat |
| Seasonal demand |
Volatile |
Produces quarterly and annual swings |
| Private-label competition |
Negative |
Pressures price and volume |
| Pseudoephedrine access restrictions |
Negative |
Reduces convenience and impulse purchasing |
| Mucinex brand awareness |
Positive |
Supports consumer and retailer preference |
| Retailer shelf placement |
Positive or negative |
Can materially affect visibility |
| Product substitution |
Negative |
Consumers may switch to nasal sprays, antihistamines, or store brands |
| Manufacturing costs |
Mixed |
Tablet production is relatively conventional, but packaging and compliance costs remain |
| Advertising |
Positive but costly |
Protects brand share and supports premium pricing |
Mucinex D should be viewed as a mature brand rather than a launch-stage growth asset. Revenue growth is more likely to come from price, package architecture, retailer distribution, and seasonal demand than from rapid prescription-style market expansion.
What is the likely revenue profile?
The product’s revenue pattern is likely to have four characteristics:
- High seasonality during cold and influenza months.
- Premium pricing relative to private-label alternatives.
- Stable but limited unit growth in a mature category.
- Margin resilience from brand pricing and established manufacturing.
Mucinex D can produce attractive cash contribution because its active ingredients are established, its dosage form is standardized, and its marketing platform is shared with the broader Mucinex franchise. The principal financial risks are category substitution, private-label erosion, and weak respiratory seasons.
Who owns Mucinex D and what licensing deals affect the product?
Reckitt owns the Mucinex brand in the United States. Reckitt acquired Adams Respiratory Therapeutics, the company associated with Mucinex, in 2008 for approximately $2.3 billion.[3] The transaction added Mucinex and related respiratory products to Reckitt’s consumer-health portfolio.
Public disclosures do not identify a separate current third-party license governing the core Mucinex D brand. The commercial rights are generally understood to sit within Reckitt’s consumer-health business. Contract-manufacturing arrangements may exist, but the company does not publicly disclose product-specific manufacturing contracts or royalty terms.
The Adams acquisition remains strategically relevant because it established Mucinex as a major respiratory brand inside Reckitt. The value of the product is tied to the broader brand family, including guaifenesin-only and multi-symptom products, rather than to Mucinex D in isolation.
What patents protect Mucinex D?
Mucinex D does not have the patent profile of a new prescription chemical entity. Guaifenesin and pseudoephedrine are long-established active ingredients, and the relevant products are regulated through the FDA’s OTC framework.
The main protection layers are:
- Trademark protection for the Mucinex brand.
- Packaging and trade dress.
- Product formulation and extended-release know-how.
- Manufacturing processes.
- Retail distribution.
- Advertising and consumer recognition.
- Regulatory compliance capabilities for pseudoephedrine sales.
Some formulation or manufacturing patents may apply to particular extended-release combinations, tablet structures, or processes. Those rights would require a product-specific patent search and claim analysis. They should not be treated as equivalent to a blocking patent on the Mucinex D brand.
Is Mucinex D listed in the FDA Orange Book?
Mucinex D is generally not expected to have an Orange Book listing comparable to a prescription drug approved through a new drug application. The FDA Orange Book primarily identifies approved prescription drug products and relevant patent and exclusivity information.[4]
OTC monograph products typically do not receive the same patent-listing and Paragraph IV framework used for prescription products. As a result:
- There is no conventional Orange Book expiration date for Mucinex D.
- There is no standard Paragraph IV litigation pathway tied to the branded product.
- Generic competitors can market compliant products without waiting for patent expiration, subject to FDA requirements and applicable intellectual-property rights.
When does Mucinex D lose exclusivity?
Mucinex D has no single statutory loss-of-exclusivity date comparable to a prescription medicine. Its commercial exclusivity is already limited because the active ingredients are longstanding OTC substances and competing products are available.
The relevant protection dates are therefore not a single patent expiration date. They include:
| Protection type |
Status |
| New chemical entity exclusivity |
Not applicable |
| Prescription drug exclusivity |
Not applicable |
| OTC monograph protection |
Product must comply with applicable FDA rules |
| Brand trademark |
Continuing protection subject to renewal and use |
| Formulation patents |
Potentially product-specific; no single public expiry establishes Mucinex D exclusivity |
| Trade dress |
Potential protection against confusingly similar presentation |
| Pseudoephedrine controls |
Regulatory barrier affecting all sellers, not just Mucinex |
FDA’s OTC monograph regulations cover active ingredients, indications, dosages, labeling, and conditions for marketing without an approved prescription-drug application. Guaifenesin and oral nasal decongestants are addressed within the OTC monograph system under 21 C.F.R. part 341.[5]
Are there Paragraph IV challenges to Mucinex D?
No conventional Paragraph IV challenge is expected to control Mucinex D market entry because the product is an OTC monograph product rather than a typical Orange Book-listed prescription drug.
A competitor can enter with an equivalent guaifenesin-pseudoephedrine product if it satisfies the applicable FDA OTC requirements and does not infringe enforceable patents or trademarks. Litigation risk could still arise from:
- Patent claims covering an extended-release formulation.
- Trade-dress claims.
- Trademark infringement.
- False advertising.
- Product labeling.
- Manufacturing or quality disputes.
- State consumer-protection claims.
These issues are distinct from the standard Abbreviated New Drug Application Paragraph IV process.
What generic and private-label launch risks exist?
Private-label competition is the largest structural threat. Retailers can sell store-brand versions of guaifenesin and pseudoephedrine at lower prices, often using similar tablet strengths and package counts.
Generic competition
Generic or store-brand products can compete on:
- Lower retail price.
- Equivalent active ingredients.
- Comparable extended-release dosing.
- Retailer-controlled shelf placement.
- Online and pharmacy availability.
Mucinex retains advantages in brand familiarity, consumer trust, advertising, and cross-selling. Those advantages are strongest when consumers purchase under time pressure during illness and recognize the Mucinex name.
Pseudoephedrine channel risk
Pseudoephedrine products must be sold under controlled retail procedures. Some pharmacies may reduce inventory because of compliance burdens, theft concerns, or lower turnover. A competitor with stronger pharmacy distribution can gain share even without a superior formulation.
Phenylephrine substitution
Phenylephrine products remain widely available in the United States, although FDA has proposed removing oral phenylephrine as an OTC nasal-decongestant active ingredient after concluding that available data do not support its effectiveness at the labeled dose.[6] Final regulatory action and implementation timing could alter demand for pseudoephedrine products, including Mucinex D.
If oral phenylephrine products are removed or reformulated, Mucinex D could benefit from substitution. The benefit would depend on consumer demand, retailer execution, physician and pharmacist recommendations, and the availability of competing pseudoephedrine combinations.
What is the FDA regulatory status of Mucinex D?
Mucinex D is marketed as an OTC product under the FDA’s nonprescription drug framework. Its commercial compliance obligations include:
- Active-ingredient eligibility.
- Dosage and strength requirements.
- Mandatory labeling.
- Age and dosing instructions.
- Warnings related to hypertension, heart disease, thyroid disease, diabetes, and other conditions.
- Pseudoephedrine transaction controls.
- Current good manufacturing practice requirements.
Pseudoephedrine-containing products face greater regulatory complexity than guaifenesin-only products. The Combat Methamphetamine Epidemic Act requires sales controls designed to limit diversion of pseudoephedrine for illicit methamphetamine production.[2]
How strong is the Mucinex D competitive position?
Mucinex D has a strong brand position but a limited legal moat.
| Dimension |
Assessment |
| Brand equity |
Strong |
| Active-ingredient differentiation |
Moderate |
| Patent exclusivity |
Limited or uncertain |
| Regulatory barrier |
Moderate because of pseudoephedrine controls |
| Private-label exposure |
High |
| Manufacturing complexity |
Moderate |
| Retail dependence |
High |
| Seasonal resilience |
Moderate |
| Pricing power |
Moderate |
| Long-term volume growth |
Low to moderate |
The strongest asset is the Mucinex respiratory franchise. The weakest point is substitutability. Consumers can choose a store brand, a separate guaifenesin product plus decongestant, a nasal spray, or a different cold remedy.
What manufacturing and intellectual-property barriers affect Mucinex D?
Manufacturing Mucinex D is more complex than producing an immediate-release single-ingredient tablet because the product must deliver controlled release of two active ingredients in a stable solid dosage form. Relevant technical requirements include:
- Uniformity of active ingredients.
- Release-rate control.
- Tablet hardness and dissolution performance.
- Stability over the labeled shelf life.
- Packaging that protects the product from moisture.
- Batch testing and content uniformity.
- Compliance with FDA current good manufacturing practice rules.
These requirements create execution barriers but do not necessarily prevent entry by an experienced generic or contract manufacturer. The technical moat is therefore meaningful at the operational level but weaker than the legal barriers associated with a patented pharmaceutical molecule.
What generic launch scenarios could affect Mucinex D?
Base case
Mucinex D maintains a premium brand position, while private-label products capture incremental volume. Reckitt supports revenue through pricing, promotional activity, and distribution. Seasonal performance remains the main source of year-to-year variability.
Downside case
Retailers expand private-label shelf space, pseudoephedrine access declines, and consumers migrate to lower-cost or nonoral products. Mucinex D experiences unit erosion, with price increases only partly offsetting volume losses.
Upside case
FDA action against oral phenylephrine shifts consumers toward pseudoephedrine products. Mucinex D gains from its recognized respiratory brand, particularly if Reckitt secures retailer inventory and pharmacist recommendation.
What patent litigation or settlement agreements affect Mucinex D?
No widely reported current patent litigation or Paragraph IV settlement is central to Mucinex D’s market position. The principal legal exposure is more likely to involve OTC advertising, labeling, trademarks, trade dress, consumer claims, or product-quality disputes than a traditional prescription-drug patent case.
A competitor’s formulation patent could create a narrower dispute, but it would not automatically provide broad exclusivity over all guaifenesin-pseudoephedrine combinations.
Key Takeaways
- Mucinex D is a mature OTC respiratory product containing extended-release guaifenesin and pseudoephedrine.
- Reckitt owns the Mucinex brand and acquired the business associated with Mucinex through its 2008 Adams Respiratory Therapeutics transaction.
- Reckitt does not disclose Mucinex D revenue separately, preventing a precise product-level financial forecast.
- The product has no conventional prescription exclusivity period or standard Paragraph IV pathway.
- Brand equity, distribution, packaging, and formulation know-how matter more than a single blocking patent.
- Private-label products are the main competitive threat.
- Pseudoephedrine sales restrictions reduce convenience but also create an operating barrier for smaller competitors.
- FDA action concerning oral phenylephrine could improve the relative position of pseudoephedrine-containing products.
- The likely financial profile is mature, seasonal, and cash generative, with growth driven mainly by pricing, mix, and category substitution.
FAQs
Does Mucinex D have a patent expiration date?
There is no single publicly controlling patent expiration date equivalent to the expiration date for a patented prescription molecule. Any relevant formulation or manufacturing patents must be evaluated individually.
Is Mucinex D a generic drug?
Mucinex D is a branded OTC product. Store-brand and generic-equivalent guaifenesin-pseudoephedrine products compete with it under the FDA OTC framework.
Can pharmacies sell Mucinex D without a prescription?
Yes. Mucinex D is sold without a prescription, but pseudoephedrine transactions are subject to identification, purchase-limit, recordkeeping, and retailer-control requirements.
Does Mucinex D compete with Mucinex DM?
Yes, but the products address different symptom combinations. Mucinex D contains pseudoephedrine, while Mucinex DM combines guaifenesin with dextromethorphan, a cough suppressant.
Could an FDA decision on phenylephrine increase Mucinex D sales?
Potentially. Removal or reformulation of oral phenylephrine products could shift some consumers toward pseudoephedrine products, including Mucinex D. The effect would depend on final FDA action and retailer response.
References
- U.S. Food and Drug Administration. (n.d.). Mucinex D extended-release tablets: Drug facts label.
- U.S. Drug Enforcement Administration. (n.d.). Pseudoephedrine, ephedrine, and phenylpropanolamine.
- Reckitt Benckiser Group plc. (2008). Annual report and financial statements 2008.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
- Electronic Code of Federal Regulations. (2024). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use.
- U.S. Food and Drug Administration. (2023). FDA proposes ending use of oral phenylephrine as an over-the-counter monograph nasal decongestant active ingredient.
